Search these posts for articles, publications, research studies & discussions relevant to Phoenix Micron products.

Phoenix MICRON Research Blog

2021

Therapeutic target for retinal degeneration studied with the Phoenix MICRON® retinal structure and function tools

In their article, “Effect of MMP-9 gene knockout on retinal vascular form and function,” George et al study the effect of knocking out a matrix protein in a mouse model of retinitis pigmentosa using the Phoenix MICRON® platform including OCT, and Ganzfeld ERG. The combination of the Phoenix MICRON® fundus images, OCT revealing the layers,

2021

A better mouse model of retinal vein occlusion with the Phoenix MICRON® laser and OCT

Retinal vein occlusion is the second most common retinal vascular disorder leading to loss of vision in developed countries (after diabetic retinopathy). A lack of treatment options is partially caused by a lack of effective animal models; most rodent models do not show the essential symptom of cystoid edema and often heal quickly. In their

2021

Stunning fundus images of GFP-positive cells demonstrate new intravitreal injection technique

In their article, “A Novel Method Combining Vitreous Aspiration and Intravitreal AAV2/8 Injection Results in Retina-Wide Transduction in Adult Mice,” Da Costa et al use the Phoenix MICRON® III imaging platform to take stunning images demonstrating the success of their novel intravitreal injection technique. Gene therapy is a promising treatment option of genetic retinopathies—adeno-associated viruses

2020

The Phoenix MICRON® IV system and OCT help evaluate promising compounds for treatment of age-related macular degeneration

Age-related macular degeneration affects tens of millions of people worldwide, leading to vision impairment and blindness. Anti-VEGF treatment helps only 25-40% of patients, leaving others with no recourse to this progressive blinding disease. In their article, “Suppression of aberrant choroidal neovascularization through activation of the aryl hydrocarbon receptor,” Choudhary et al explore potential treatment using

2020

A year-long longitudinal pattern dystrophy fundus study with the Phoenix MICRON® IV imaging platform

In their 2019 paper, “Novel molecular mechanisms for Prph2‐associated pattern dystrophy,” Chakraborty et al use the Phoenix MICRON® IV retinal imaging platform to longitudinally study the effect of a very specific mutation affecting the Peripherin 2 protein. Peripherin 2 is a protein in rods and cones which, if mutated, can lead to retinitis pigmentosa, cone-rod

2020

RPE mutations lead to retinal hypopigmentation, vasculature changes, and decreased function

In their paper, “The microphthalmia-associated transcription factor (Mitf) gene and its role in regulating eye function,” García-Llorca et al use the Phoenix MICRON® IV to examine the outer eye appearance, retinal pigmentation, and retinal vasculature through fluorescein angiography to study several different mouse mutants. Combined with electroretinography and histology, the fundus images tell a story

1 2 3 4 5 6 9